Spirulina.Guru

Science

Spirulina and dysautonomia.

Dysautonomia describes dysfunction of the autonomic nervous system — the involuntary control system regulating heart rate, blood pressure, and blood vessel tone in response to positional and environmental changes. POTS (postural orthostatic tachycardia syndrome) is the most common form in young adults, particularly women. Iron deficiency, impaired endothelial function, and reduced blood volume are all treatable contributors that spirulina addresses.

Dysautonomia types

  • POTS: A sustained heart rate increase of ≥30 bpm (or ≥40 bpm in those under 19) within 10 minutes of standing, without orthostatic hypotension. Mechanisms include reduced venous return (blood pooling in legs), impaired reflex vasoconstriction, reduced blood volume, and in some patients autoimmune adrenergic receptor antibodies. Associated with hEDS, long COVID, MCAS, and autoimmune conditions.
  • Orthostatic hypotension: Sustained blood pressure drop of ≥20/10 mmHg on standing. More common in older adults, Parkinson’s disease, diabetic autonomic neuropathy, Addison’s disease, and medication-induced (alpha-blockers, antihypertensives).
  • Vasovagal syncope: Reflex syncope from excessive parasympathetic response to triggers (pain, prolonged standing, heat). Not structural autonomic dysfunction.

Iron deficiency in POTS/dysautonomia

  • Iron deficiency is significantly more prevalent in POTS patients than the general population, particularly in young women with heavy menstrual blood loss. Iron deficiency worsens orthostatic intolerance through multiple mechanisms: reduced oxygen delivery to muscles during postural change (reduced haemoglobin); autonomic dysfunction exacerbated by anaemia-induced compensatory heart rate elevation; reduced red blood cell mass contributing to relative hypovolaemia.
  • Ferritin target in POTS: >75 µg/L recommended by many dysautonomia specialists (higher than the standard laboratory reference range). Below this level, symptoms worsen even without overt anaemia. Spirulina iron (2–4 mg/5 g) contributes to daily iron intake. Add vitamin C in the same meal to improve non-haem iron absorption. Avoid calcium-containing supplements at the same time.

Endothelial NO and vascular tone

  • Endothelial dysfunction (impaired NO-mediated vasodilation) contributes to abnormal vascular tone responses in POTS. Spirulina phycocyanobilin inhibits endothelial NOX2, reducing superoxide-mediated NO quenching and increasing bioavailable NO. In POTS, this effect could theoretically improve basal endothelial vascular tone and peripheral resistance regulation. However, in orthostatic hypotension requiring vasoconstriction to maintain standing blood pressure, any vasodilatory tendency from spirulina is counterproductive: take with the largest salt-loading meal to contextualise any vasodilatory effect within the volume-loading strategy.

MCAS overlap

  • Mast cell activation syndrome (MCAS) co-occurs with POTS in an estimated 17–50% of cases. MCAS involves pathological mast cell degranulation releasing histamine, prostaglandins, and tryptase. Histamine from MCAS causes vasodilation and worsens orthostatic symptoms. Spirulina has mixed effects in MCAS: GLA pathway may reduce leukotriene production; spirulina polysaccharides and protein may trigger mast cell degranulation in reactive individuals. If MCAS is diagnosed alongside POTS: start spirulina at 0.1 g/day; increase 0.1 g/week; wait 24–48 hours at each step to detect any MCAS-type reactions (flushing, urticaria, GI cramping, palpitations).

Drug interactions

Fludrocortisone (POTS, orthostatic hypotension)

  • Fludrocortisone (Florinef) is a mineralocorticoid that increases sodium retention and blood volume, improving orthostatic tolerance. No pharmacokinetic interaction with spirulina. Spirulina potassium (~400 mg/10 g) is relevant: fludrocortisone causes potassium loss via renal excretion; spirulina potassium supplementation alongside fludrocortisone may partially compensate for this kaliuretic effect, but monitor serum potassium in the first 2–4 weeks after starting spirulina on fludrocortisone.

Beta-blockers (propranolol, metoprolol in POTS)

  • Low-dose beta-blockers reduce the heart rate response in POTS. No pharmacokinetic interaction with spirulina. Spirulina endothelial effects are unlikely to be clinically significant alongside beta-blocker therapy.

Ivabradine

  • Ivabradine (Ifchannel blocker, reduces sinus rate without affecting contractility) is used in POTS. No pharmacokinetic interaction with spirulina. Note: CYP3A4 metabolises ivabradine; no documented spirulina CYP3A4 inhibition.

Midodrine (alpha-1 agonist, orthostatic hypotension)

  • Midodrine increases peripheral vascular resistance to maintain standing blood pressure. In orthostatic hypotension: spirulina’s endothelial NO vasodilatory tendency may mildly oppose midodrine’s vasoconstrictive effect. At 3–5 g/day spirulina, this opposition is not expected to be clinically meaningful, but monitor for worsening orthostatic symptoms.

Practical guidance

  • POTS: check ferritin and transferrin saturation; target ferritin >75 µg/L for symptom optimisation; spirulina iron + vitamin C contributes to iron repletion
  • POTS + MCAS overlap: start at 0.1 g/day; increase 0.1 g/week; 24–48h observation at each step for MCAS reactions
  • On fludrocortisone: monitor serum potassium 2–4 weeks after starting spirulina; spirulina K (~400 mg/10 g) may partially offset fludrocortisone-induced kaliuresis
  • Take spirulina with salt-loading meals (the primary POTS management strategy) to contextualise any vasodilatory effect within volume expansion
  • Orthostatic hypotension on midodrine: monitor for worsening orthostatic symptoms; the net effect is expected to be minor at standard spirulina doses

Related reading

Get the weekly digest

Curated science, recipes, and brand intel — once a week, no spam, unsubscribe in one click.